Radioimmunotherapy for CD20-positive B-cell non-hodgkin's lymphoma

Community Oncology

Volumn 8, Issue 1, 2011, Pages 24-31

  Lee, Peter P ^a   Rosen, Peter J ^b  

^a Tower Cancer Research Foundation ^*  (United States)

^b Providence Saint Joseph Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTHRAQUINONE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; PREDNISOLONE; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CYTOPENIA; DRUG APPROVAL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SAFETY; DRUG UTILIZATION; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; HEPATITIS B; HUMAN; HYPOTHYROIDISM; INJECTION SITE REACTION; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OFF LABEL DRUG USE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RADIOIMMUNOTHERAPY; REVIEW; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT INDICATION;

EID: 79551712373     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(12)70004-9     Document Type: Review

References (39)

1. Grillo-LÓpez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999;26(5 suppl 14):66-73.
2. McLaughlin P, Grillo-LÓpez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed in-dolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833.
3. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-1932.
4. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstrom's macro- globulinemia with rituximab. J Clin Oncol 2002;20:2327-2333.
5. Kalpadakis C, Pangalis GA, Dimopoulou MN, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 2007;25:127-131.
6. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116:2040-2045.
7. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579-4586.
8. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-la-bel, phase 3 trial. Lancet 2010;376:1164-1174.
9. Salles GA, Seymour JF, Feugier P, et al. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemo- therapy. J Clin Oncol 2010;2815S]:8004.
10. Illidge TM. Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date? J Clin Oncol 2010;28:2944-2946.
11. Cardarelli PM, Quinn M, Buckman D, et al. Binding to CD20 by anti-B1 antibody or F(ab′)2 is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002;51:15-24.
12. Lehnert M, Ludwig H, Zojer N. Up- date on the rational use of Y-ibritumomab tiux- etan in the treatment of follicular lymphoma. Onco Targets Ther 2009;2:199-208.
13. Jacobs SA, Vidnovic N, Joyce J, Mc-Cook B, Torok F, Avri N. Full-dose 90Y ibritu- momab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer Res 2005;11(19 pt 2):7146s-7150s.
14. Niitsu N, Hagiwara Y, Tanae K, Kohri M, Takahashi N. Prospective analysis of hepatitis B virus reactivation in patients with dif- fuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol 2010;28:5097-5100.
15. Paues J, Vrethem M. Fatal progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma treated with rituximab. J Clin Virol 2010;48:291-293.
16. Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodys- plastic syndrome and acute myelogenous leu- kemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 2007;25:4285-4292.
17. 131I tositumomab). Bone Mar- row Transplant 2002;29:523-525.
18. Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritu- momab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3885-3890.
19. Witzig, TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium- 90-labeled ibritumomab tiuxetan radioimmu- notherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-2463.
20. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radio-immunotherapy in patients with rituximab-re-fractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262-3269.
21. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmuno- therapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombo- cytopenia: a phase II multicenter trial. Blood 2002;99:4336-4342.
22. Schilder R, Molina A, Bartlett N, et al. Follow-up results of a phase II study of ibri- tumomab tiuxetan radioimmunotherapy in pa- tients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Can- cer Biother Radiopharm 2004;19:478-481.
23. Emmanouilides C, Witzig TE, Gor-Don LI, et al. Treatment with yttrium 90 ibri- tumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lympho-ma 2006;47:629-636.
24. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation ther- apy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156-5164.
25. Goff L, Summers K, Iqbal S, et al. Quantitative PCR analysis for Bcl-2/IgH in a phase III study of yttrium-90 ibritumomab tiuxetan as consolidation of first remission in patients with follicular lymphoma. J Clin On- col 2009;27:6094-6100.
26. Smith MR, Zhang L, Gordon LI, et al. Phase II study of R-CHOP followed by 90Y- ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group Study E1499. Blood 2007;110:389.
27. Morschhauser F, Illidge T, Huglo D, et al. Efficacy and safety of yttrium-90 ibritu- momab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplan- tation. Blood 2007;110:54-58.
28. Wang M, Oki Y, Pro B, et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:5213-5218.
29. Jacobs SA, Swerdlow SH, Kant J, et al. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreat- ed follicular lymphoma. Clin Cancer Res 2008;14:7088-7094.
30. Hainsworth JD, Spigel DR, Markus TM, et al. Rituximab plus short-duration che- motherapy followed by yttrium-90 ibritumom- ab tiuxetan as first-line treatment for patients with follicular non-Hodgkin's lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma My- eloma 2009;9:223-228.
31. Zinzani PL, Rossi G, Franceschetti S, et al. Phase II trial of short-course R-CHOP fol- lowed by 90Y-ibritumomab tiuxetan in previ- ously untreated high-risk elderly diffuse large B-cell lymphoma patients. Clin Cancer Res 2010;16:3998-4004.
32. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tosi- tumomab for chemotherapy-relapsed/refrac- tory low-grade and transformed low-grade B- cell non-Hodgkin's lymphomas. J Clin Oncol 2000;18:1316-1323.
33. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-3928.
34. Horning SJ, Younes A, Jain V, et al. Ef- ficacy and safety of tositumomab and iodine- 131 tositumomab (Bexxar) in B-cell lympho- ma, progressive after rituximab. J Clin Oncol 2005;23:712-719.
35. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treat- Volume 8/Number 1 ment for follicular lymphoma. N Engl J Med 2005;352:441-449.
36. Kaminski MS, Estes J, Tuck M, Ross CW, Wahl RL. I131-tositumomab monother- apy as frontline treatment for follicular lym- phoma: updated results after a median follow- up of 8 years. J Clin Oncol 2007;2518S]:8033.
37. Press OW, Unger JM, Braziel RM, et al. A phase 2 trial of CHOP chemother- apy followed by tositumomab/iodine I 131 tositumomab for previously untreated fol- licular non-Hodgkin lymphoma: South- west Oncology Group Protocol S9911. Blood 2003;102:1606-1612.
38. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tosi- tumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow- up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143-4149.
39. Link BK, Martin P, Kaminski MS, Goldsmith SJ, Coleman M, Leonard JP. Cy-Clophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-Grade follicular lymphoma: eight-year follow- up of a multicenter phase II study. J Clin Oncol 2010;28:3035-3041